
Rocket Pharmaceuticals Cleared to Resume Phase 2 RP-A501 Study in Danon Disease
Rocket Pharmaceuticals Announces FDA Lifts Clinical Hold on Pivotal Phase 2 Trial of RP-A501 in Danon Disease Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a…












